Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition

Mucosal Immunology

Volumn 10, Issue 6, 2017, Pages 1480-1490

  Hearps, A C ^a,b   Tyssen, D ^a   Srbinovski, D ^a,b   Bayigga, L ^c   Diaz, D J D ^a,b   Aldunate, M ^a,b   Cone, R A ^d   Gugasyan, R ^a,b   Anderson, D J ^c   Tachedjian, G ^a,b,e,f  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RANTES; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SEMINAL PLASMA; UTERINE CERVIX EPITHELIUM; VAGINA FLORA; CELL LINE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; INFLAMMATION; LACTOBACILLUS; METABOLISM; MICROFLORA; PATHOLOGY; PHYSIOLOGY; VAGINA; VIROLOGY;

ANTI-INFLAMMATORY AGENTS; CELL LINE; CYTOKINES; EPITHELIAL CELLS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LACTIC ACID; LACTOBACILLUS; MICROBIOTA; VAGINA;

EID: 85030682323     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2017.27     Document Type: Article

References (52)

1. UNAIDS. The Gap report (2014). http://files.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2014/UNAIDS-Gap-report- en.pdf.
2. Abdool Karim, Q., Sibeko, S. & Baxter, C. Preventing HIV infection in women: a global health imperative. Clin. Infect. Dis. 50 (Suppl 3), S122-S129 (2010).
3. Aldunate, M. et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front. Physiol. 6, 164 (2015).
4. Ravel, J. et al. Vaginal microbiome of reproductive-age women. Proc. Natl Acad. Sci. USA 108 (Suppl 1), 4680-4687 (2011).
5. Martin, H.L. et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180, 1863-1868 (1999).
6. Borgdorff, H. et al. Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. ISME J. 8, 1781-1793 (2014).
7. Taha, T.E. et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12, 1699-1706 (1998).
8. Sha, B.E. et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 191, 25-32 (2005).
9. Cohen, C.R. et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 9, e1001251 (2012).
10. Anahtar, M.N. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42, 965-976 (2015).
11. Borgdorff, H. et al. Cervicovaginal microbiome dysbiosis is associatedwith proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol. 9, 621-633 (2016).
12. Masson, L. et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm. Infect. 90, 580-587 (2014).
13. Gosmann, C. et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 46, 29-37 (2017).
14. Masson, L. et al. Genital inflammation and the risk of HIV acquisition in women. Clin. Infect. Dis. 61, 260-269 (2015).
15. Freeman, E.E., Weiss, H.A., Glynn, J.R., Cross, P.L., Whitworth, J.A. & Hayes, R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73-83 (2006).
16. Passmore, J.S., Jaspan, H.B. & Masson, L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr. Opin. HIV AIDS 11, 156-162 (2016).
17. Arnold, K.B. et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 9, 194-205 (2016).
18. Ferreira, V.H. et al. Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J. Infect. Dis. 204, 299-308 (2011).
19. Li, Q. et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038 (2009).
20. Herbst-Kralovetz, M.M. et al. Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am. J. Reprod. Immunol. 59, 212-224 (2008).
21. Doerflinger, S.Y., Throop, A.L. & Herbst-Kralovetz, M.M. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J. Infect. Dis. 209, 1989-1999 (2014).
22. Pyles, R.B. et al. Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS ONE 9, e93419 (2014).
23. Rose, W.A. 2nd, McGowin, C.L., Spagnuolo, R.A., Eaves-Pyles, T.D., Popov, V.L. & Pyles, R.B. Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoSONE7, e32728 (2012).
24. O'Hanlon, D.E., Moench, T.R. & Cone, R.A. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect. Dis. 11, 200 (2011).
25. Aldunate, M. et al. Vaginal concentrations of lactic acid potently inactivate HIV. J. Antimicrob. Chemother. 68, 2015-2025 (2013).
26. O'Hanlon, D.E., Moench, T.R. & Cone, R.A. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoSONE8, e80074 (2013).
27. Anderson, D.J., Marathe, J. & Pudney, J. The structure of the human vaginal stratum corneum and its role in immune defense. Am. J. Reprod. Immunol. 71, 618-623 (2014).
28. Yazdi, A.S. & Ghoreschi, K. The interleukin-1 family. Adv. Exp. Med. Biol. 941, 21-29 (2016).
29. Granowitz, E.V., Clark, B.D., Vannier, E., Callahan, M.V. & Dinarello, C.A. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79, 2356-2363 (1992).
30. Nazli, A. et al. HIV-1 gp120 induces TLR2-and TLR4-mediated innate immune activation in human female genital epithelium. J. Immunol. 191, 4246-4258 (2013).
31. Boskey, E.R., Cone, R.A., Whaley, K.J. & Moench, T.R. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum. Reprod. 16, 1809-1813 (2001).
32. Ayehunie, S. et al. Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products. Toxicol. In Vitro 20, 689-698 (2006).
33. Robertson, S.A. Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res. 322, 43-52 (2005).
34. Sharkey, D.J., Macpherson, A.M., Tremellen, K.P. & Robertson, S.A. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol. Hum. Reprod. 13, 491-501 (2007).
35. Mossop, H., Linhares, I.M., Bongiovanni, A.M., Ledger,W.J. & Witkin, S.S. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. Obstet. Gynecol. 118, 840-846 (2011).
36. Witkin, S.S.,Mendes-Soares, H., Linhares, I.M., Jayaram, A., Ledger,W.J. & Forney, L.J. Influence of vaginal bacteria and D-and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. MBio 4, e00460-e00513 (2013).
37. Menard, S., Candalh, C., Bambou, J.C., Terpend, K., Cerf-Bensussan, N. & Heyman, M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53, 821-828 (2004).
38. Lee, J.M., Hwang, K.T., Jun,W.J., Park, C.S. & Lee, M.Y. Antiinflammatory effect of lactic acid bacteria: inhibition of cyclooxygenase-2 by suppressing nuclear factor-kappaB in Raw264.7 macrophage cells. J. Microbiol. Biotechnol. 18, 1683-1688 (2008).
39. Peter, K., Rehli, M., Singer, K., Renner-Sattler, K. & Kreutz, M. Lactic acid delays the inflammatory response of human monocytes. Biochem. Biophys. Res. Commun. 457, 412-418 (2015).
40. Prakash, M., Patterson, S., Gotch, F. & Kapembwa, M.S. Recruitment of CD4 T lymphocytes and macrophages into the cervical epithelium of women after coitus. Am. J. Obstet. Gynecol. 188, 376-381 (2003).
41. Verstraelen, H., Vervaet, C. & Remon, J.P. Rationale and safety assessment of a novel intravaginal drug-delivery system with sustained DL-Lactic acid release, intended for long-term protection of the vaginal microbiome. PLoS ONE 11, e0153441 (2016).
42. Hemmerling, A. et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm. Dis. 37, 745-750 (2010).
43. Larsson, P.G., Stray-Pedersen, B., Ryttig, K.R. & Larsen, S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 8, 3 (2008).
44. Keller, M.J. et al. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS ONE 7, e46901 (2012).
45. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
46. Naranbhai, V. et al. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J. Infect. Dis. 206, 993-1001 (2012).
47. Biswas, N. et al. Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract. Antimicrob. Agents Chemother. 58, 6444-6453 (2014).
48. Baeten, J.M. et al. A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women. 23rd Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA (2016).
49. Fichorova, R.N., Rheinwald, J.G. & Anderson, D.J. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissuespecific differentiation proteins. Biol. Reprod. 57, 847-855 (1997).
50. Tyssen, D. et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS ONE 5, e12309 (2010).
51. Price, C.F. et al. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 6, e24095 (2011).
52. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001).